Enhancing Diagnosis and Access to Treatment in EoE: What You Need to Know from Your Patients
Speakers: Mirna Chehade, MD, MPH, AGAF, FAAAAI, Professor of Pediatrics and MedicineKathryn Peterson, MD, MSci, Professor of Medicine
Duration: 60 minutes
Presented on: September 29, 2023
Mirna Chehade, MD, MPH, AGAF, FAAAAI
Mirna Chehade, MD, MPH, AGAF, FAAAAI
Professor of Pediatrics and MedicineMirna Chehade, MD, MPH is a professor of pediatrics and medicine at the Icahn School of Medicine at Mount Sinai in New York City. She is a board-certified pediatric gastroenterologist and the founding director of the Mount Sinai Center for Eosinophilic Disorders (MSCED). The center provides cutting-edge clinical care, research, and support for patients with eosinophilic gastrointestinal diseases (EGIDs) including eosinophilic esophagitis (EoE). She is an active member in national and international organizations, and has several publications on EGIDs, including the efficacy and safety of various therapies for EGIDs, potential reasons EGIDs are missed, and long-term outcomes of EGIDs. She is a frequently invited speaker at national and international meetings, and an invited reviewer for several highly ranked gastroenterology and allergy journals.
Kathryn Peterson, MD, MSci
Kathryn Peterson, MD, MSci
Professor of MedicineKathy Peterson, MD is a professor of medicine at the University of Utah in Salt Lake City. She also co-directs the multidisciplinary clinic for gastrointestinal eosinophilic disorders. Her specialties lie in the diagnosis and treatment of diseases of the digestive system, including eosinophilic esophagitis, Barrett’s esophagus, and inflammatory bowel disease. Her research focuses on novel methods to diagnose, risk stratify, and treat eosinophilic esophagitis and other eosinophilic gastrointestinal diseases (EGIDs). She completed her medical degree at the University of Texas Southwestern in Dallas, followed by a residency and fellowship at the University of Utah and a master’s program in epidemiology at Harvard University in Boston, MA.
Enhancing Diagnosis and Access to Treatment in EoE: What You Need to Know from Your PatientsThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Asthma and Allergy Foundation of America (AAFA).
ACKNOWLEDGEMENTThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
DATE OF RELEASE/EXPIRATIONThis activity was released on September 29, 2023 and is valid until September 29, 2024. Requests for credit must be made no later than September 29, 2024.
TARGET AUDIENCEThe educational design of this activity addresses the needs of gastroenterologists, pediatric gastroenterologists, allergists, immunologists, specialty NPs and PAs, and other clinicians involved in the management of patients with eosinophilic esophagitis (EoE).
STATEMENT OF NEED/PROGRAM OVERVIEWSigns and symptoms of eosinophilic esophagitis (EoE) can be easily missed or misinterpreted, especially if patients have adopted adaptive behaviors to cope with pain while eating. In addition, while new therapeutic options are becoming available, the most recent guidelines still discuss them as options only accessible as part of trial participation. In the meantime, the FDA granted approval to the first biologic agent for the management of EoE in patients ages 12 and older, and data are accumulating on the potential role of T2-targeted agents in younger patients.
Join a panel of gastroenterologists to learn about signs and symptoms of EoE in babies, children, and adults. Panelists will provide guidance on diagnosis of EoE, discuss the importance of asking questions to uncover adaptive behaviors, and share details of the current treatment paradigm. Participating clinicians will also learn about evidence-based guidelines, expert recommendations, and data on new targeted agents for the management of EoE in children and adults.
Do you have patients at risk for or with EoE who could use education on eating habits related to EoE and new treatment options? Direct your patients to MedLive.com to access the activity, “Difficulty Eating? Talk, Do Not Adapt! This Could Be Eosinophilic Esophagitis (EoE).”
EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:
- Collect a thorough patient history, asking about symptoms and adaptive behaviors that may call for evaluation for EoE
- Summarize data related to biologic therapy targeting T2 inflammation to manage EoE in children, adolescents, and adults
- Outline recent expert guidance on the place of biologic agents in the management of EoE to enhance patient quality of life, safety, and growth
PHYSICIAN ACCREDITATION STATEMENTThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATIONGlobal Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 1 hour to complete.
INSTRUCTIONS TO RECEIVE CREDITIn order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICYThere is no fee for this educational activity.
DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPSGlobal Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Mirna Chehade, MD, MPH, AGAF, FAAAAI
Professor of Pediatrics and Medicine
Founding Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
Consulting Fee: Adare/Ellodi, Allakos, AstraZeneca, Bristol Myers Squibb, Nexstone Immunology, Phathom, Recludix Pharma, Regeneron, Sanofi, Shire/Takeda
Contracted Research: Adare/Ellodi, Allakos, AstraZeneca, Bristol Myers Squibb, Danone, Regeneron, Shire/Takeda
Kathryn Peterson, MD, MSci
Professor of Medicine
University of Utah
Consulting Fee: Alladapt, AstraZeneca, Allakos, Bristol Meyers Squibb, Ellodi, Invea, Lucid, Nexstone, Regeneron, Takeda
Contracted Research: AstraZeneca, Allakos, Adare, Regeneron-Sanofi, Revolo, Celldex, Ellodi Allakso and Chobani
Honoraria: Alladapt, AstraZeneca, Allakos, Bristol Meyers Squibb, Ellodi, Invea, Lucid, Nexstone, Regeneron, Takeda
Speakers' Bureau: Regeneron, Takeda, Allakos, Stock Option Holder: Nexeos Bio
Adult with EoE
Nothing to disclose
The planners and managers at Global Education Group and PlatformQ Health Education, LLC have no relevant financial relationships to disclose.
DISCLOSURE OF UNLABELED USEThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Accreditation Support:For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org
Technical Support:For any technical issues or issues with your CME Certificate, please contact, ImmunologyLive, at 877-394-1306 or at Support@ImmunologyLive.com.